Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of setmelanotide in acquired hypothalamic obesity
jRCT2041230156Phase 3Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jun 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, double-blind trial in hypothalamic obesity (HO) comparing Setmelanotide with Placebo (2 arms). Started Jun 2024; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on jRCT2041230156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230156.